Abstract
Background
Since antipsychotics induce hyperprolactinemia via the dopamine D2 receptor, long-term administration may be a risk factor for developing breast tumors, including breast cancer. On the other hand, some antipsychotic drugs have been reported to suppress the growth of breast cancer cells in vitro. Thus, it is not clear whether the use of antipsychotics actually increases the risk of developing or exacerbating breast tumors. The purpose of this study was to clarify the effects of antipsychotic drugs on the onset and progression of breast tumors by analyzing an adverse event spontaneous reporting database and evaluating the proliferation ability of breast cancer cells.
Methods
Japanese Adverse Drug Event Report database (JADER) reports from April 2004 to April 2019 were obtained from the Pharmaceuticals and Medical Devices Agency (PMDA) website. Reports of females only were analyzed. Adverse events included in the analysis were hyperprolactinemia and 60 breast tumor-related preferred terms. The reporting odds ratio (ROR), proportional reporting ratio (PRR), and information component (IC) were used to detect signals. Furthermore, MCF-7 cells were treated with haloperidol, risperidone, paliperidone, sulpiride, olanzapine and blonanserin, and cell proliferation was evaluated by WST-8 assay.
Results
In the JADER analysis, the IC signals of hyperprolactinemia were detected with sulpiride (IC, 3.73; 95% CI: 1.81–5.65), risperidone (IC, 3.69; 95% CI: 1.71–5.61), and paliperidone (IC, 4.54; 95% CI: 2.96–6.12). However, the IC signal of breast tumors was not observed with any antipsychotics. In cell-based experiments, MCF-7 cells were treated with six antipsychotics at concentrations of 2 and 32 μM, and none of the drugs showed any growth-promoting effects on MCF-7 cells. On the other hand, blonanserin markedly suppressed the growth of MCF-7 cells at a concentration of 32 μM, and the effect was concentration dependent.
Conclusions
Analysis of the JADER using the IC did not show breast tumor signals due to antipsychotic drugs. In in vitro experiments, antipsychotics did not promote MCF-7 cell proliferation whereas blonanserin suppressed MCF-7 cell growth. Further research on the effects of blonanserin on the onset and progression of breast tumor is expected.
Keywords: Breast tumor, Antipsychotics, JADER, MCF-7, Blonanserin
Background
Antipsychotics are used for the treatment of mental disorders, such as schizophrenia, and they are often taken over a long period of time. Many antipsychotics have a dopamine D2 receptor blocker actions, and hyperprolactinemia is a known side effect [1]. Long-term hyperprolactinemia increases the risk of developing osteoporosis and breast cancer [2, 3].
The prevalence of breast cancer is highest among cancers in women and in the leading cause of cancer death and disability-adjusted life-years for women in a 2017 global cancer morbidity and mortality report [4]. There have been several reports on the relationship between breast cancer and antipsychotics [3], and higher blood prolactin levels are associated with a higher risk of breast cancer, especially hormone receptor-positive and postmenopausal breast cancers [5]. A case-control study examining the association between antipsychotic drug use and breast cancer development found that there was no association between antipsychotic drug use and breast cancer risk but that there may be a slightly increased risk for ER-positive breast cancer [6]. However, there are reports that deny the association between breast cancer and the use of antipsychotics [7, 8], and no conclusions on this matter have been reached.
On the other hand, some antipsychotics have been confirmed in vitro to have growth inhibitory effects on breast cancer cells. For example, it was reported that pimozide and haloperidol had growth inhibitory effects on MCF-7 cells, whereas clozapine did not affect growth [9, 10]. It has also been reported that aripiprazole, which is an atypical antipsychotic, suppresses the growth of breast cancer cells such as MCF-7 cells and is comparable to an antineoplastic drug [11].
Therefore, we first analyzed the use of antipsychotics and the onset of breast tumors, including breast cancer, using the Japanese Adverse Drug Event Report database (JADER). The JADER is a Japanese drug side effect database managed by PMDA. Database information have been collected since 2004 and published since 2012. Qualitative evaluation by signal detection while using such a database serves as a guide for screening adverse events (AEs) specific to a drug. However, there are no reports on the risk of developing breast tumors in the JADER analysis. We analyzed not only breast cancer but also hyperprolactinemia, which is considered a risk factor for breast cancer.
Next, to clarify the direct effects of antipsychotics on the growth of breast cancer cells, we treated MCF-7 cells with antipsychotics that were shown to have the potential to influence the development of breast tumor based on JADER analysis and assessed cell proliferation.
Materials and methods
Signal detection in JADER
JADER AE reports were obtained from the PMDA website (https://www.pmda.go.jp/safety/info-services/drugs/adr-info/suspected-adr/0003.html). The database consists of four datasets in csv format: patient demographic information (DEMO), drug information (DRUG), AE information (REAC), and primary disease information (HIST). These tables can be connected using the case ID number. We analyzed data from April 2004 to April 2019. The analysis was performed on data only from females. In the DRUG table, the item “participation of drug” included only “suspected drugs.” The names of the AEs used in the JADER are standardized in the preferred term (PT) of the Medical Dictionary for Regulatory Activities (MedDRA). The AEs of breast tumors were identified by PTs included in the MedDRA defined “HLT: benign and malignant breast neoplasms” (Table 1). They were coded according to MedDRA version 22.0.
Table 1.
Preferred terms included in the “benign and malignant breast neoplasms” used in this study
| PT | code |
|---|---|
| Benign breast neoplasm | 10004243 |
| Breast cancer | 10006187 |
| Breast cancer in situ | 10006189 |
| Breast cancer recurrent | 10006198 |
| Breast cancer stage I | 10006199 |
| Breast cancer stage II | 10006200 |
| Breast cancer stage III | 10006201 |
| Breast cancer stage IV | 10006202 |
| Breast cyst | 10006220 |
| Breast hyperplasia | 10006256 |
| Breast neoplasm | 10006279 |
| Fibroadenoma of breast | 10016613 |
| Fibrocystic breast disease | 10016621 |
| Haemangioma of breast | 10018820 |
| Inflammatory carcinoma of breast recurrent | 10021977 |
| Inflammatory carcinoma of breast stage III | 10021978 |
| Inflammatory carcinoma of breast stage IV | 10021979 |
| Inflammatory carcinoma of the breast | 10021980 |
| Intraductal papilloma of breast | 10022781 |
| Lipoma of breast | 10024616 |
| Medullary carcinoma of breast | 10027095 |
| Metastases to breast | 10027454 |
| Paget’s disease of nipple | 10033364 |
| Malignant nipple neoplasm male | 10053128 |
| Malignant nipple neoplasm female | 10053129 |
| Breast cancer metastatic | 10055113 |
| Nipple neoplasm | 10056286 |
| Breast cancer female | 10057654 |
| Breast cancer male | 10061020 |
| Malignant nipple neoplasm | 10062051 |
| Breast adenoma | 10063087 |
| Breast fibroma | 10063088 |
| HER2 positive breast cancer | 10065430 |
| Apocrine breast carcinoma | 10066206 |
| Breast sarcoma | 10068582 |
| Breast sarcoma metastatic | 10068583 |
| Breast sarcoma recurrent | 10068584 |
| Oestrogen receptor positive breast cancer | 10070577 |
| Phyllodes tumour | 10071776 |
| Benign nipple neoplasm | 10072040 |
| Breast cyst rupture | 10072812 |
| Breast angiosarcoma | 10072813 |
| Breast angiosarcoma metastatic | 10072814 |
| Intraductal proliferative breast lesion | 10073094 |
| Invasive ductal breast carcinoma | 10073095 |
| Invasive lobular breast carcinoma | 10073096 |
| Invasive papillary breast carcinoma | 10073098 |
| Lobular breast carcinoma in situ | 10073099 |
| Metaplastic breast carcinoma | 10073100 |
| Mucinous breast carcinoma | 10073101 |
| Neuroendocrine breast tumour | 10073103 |
| Tubular breast carcinoma | 10073104 |
| Intraductal papillary breast neoplasm | 10073540 |
| Triple negative breast cancer | 10075566 |
| Invasive breast carcinoma | 10075713 |
| Hormone refractory breast cancer | 10076935 |
| Haemorrhagic breast cyst | 10077443 |
| Intracystic breast papilloma | 10078162 |
| Squamous cell breast carcinoma | 10079307 |
| Primary breast lymphoma | 10081036 |
The four tables constituting the JADER were subjected to deduplication and data combination using JMP pro 14.1.0 (SAS Institute Inc., Cary, NC, US). ROR, PRR, and IC were used for signal detection. The ROR was based on a paper by Kenneth J Rothman et al. [12], and a signal was present when the lower limit of the 95% CI exceeded 1. The PRR was based on a paper by S J Evans et al. [13] and a signal was present when the following criteria were met: PRRs ≥2, χ2 ≥ 4, and n ≥ 3. The IC was based on a paper by A Bate et al. [14], and a signal was present when the lower limit of the 95% CI exceeded 0.
The antipsychotic drugs analyzed in this study are N05A in the WHO ATC classification, and there are 29 drugs of the group marketed in Japan as of August 2019.
Effects of antipsychotics on breast cancer cell proliferation
Materials
Haloperidol, sulpiride, risperidone, paliperidone, blonanserin and olanzapine were purchased from Tokyo Chemical Industry (Tokyo Japan). Dimethyl sulfoxide (DMSO) and tamoxifen citrate were purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, JAPAN). All drugs were dissolved in DMSO to a final DMSO concentration of 0.5%. The Cell Counting Kit-8 was purchased from Dojindo Molecular Technologies (Kumamoto, Japan).
Cell culture
MCF-7 cells (ATCC, Manassas, VA) were cultured in RPMI-1640 medium (SIGMA-Aldrich, MO, USA) containing 10% FBS (BIOWEST, France), 80 μg/mL kanamycin (SIGMA-Aldrich, MO, USA), and 0.3 mg/mL L-glutamine (SIGMA-Aldrich, MO, USA) at 37 °C with 5% CO2 confluent cultures passaged by trypsinization (FUJIFILM Wako Pure Chemical Corporation, Osaka, JAPAN).
WST-8 assay
MCF-7 cells (2.5 × 103/well) were seeded in 96-well plates and incubated for 24 h. Then, the cells were treated with different concentrations of antipsychotics and tamoxifen citrate. The medium was exchanged 48 h after seeding the cells. After treatment for 72 h, the cells were washed with PBS. Then, 100 μL 10% FBS-RPMI+ 10 μL WST-8 solution was added to each well and incubated for an additional 1 h at 37 °C with 5% CO2. Absorbance at 450 nm was measured with a microplate reader (DS Pharma Biomedical, Osaka, Japan). All assays were replicated three times.
Statistical analysis
JMP pro14.1.0 was used for statistical analysis. The results are shown as the mean ± S.E. or S.D. Data were analyzed by one-way analysis of variance combined with Dunnett’s test or Tukey’s test. P < 0.05 was considered to indicate a statistically significant difference.
Results
JADER analysis
The total number of JADER cases reported was 6,339,117, and 703,846 cases of data from women with duplicate data deleted were analyzed. The analysis results are shown in Tables 2 and 3. Among the conditions reports for 29 antipsychotics, “hyperprolactinemia” was reported for 9 antipsychotics, and “benign and malignant breast neoplasms” were reported for 10 antipsychotics. There were six antipsychotics, namely, haloperidol, paliperidone, risperidone, sulpiride, olanzapine, and blonanserin, for which both “hyperprolactinemia” and “benign and malignant breast neoplasms” were reported.
Table 2.
Signal scores for antipsychotics-associated “Benign and malignant breast neoplasms”
| total a) | Benign and malignant breast neoplasms | |||||
|---|---|---|---|---|---|---|
| n | ROR (95%CI) | PRR (X2) | IC (95%CI) | |||
| Typical antipsychotic | ||||||
| Haloperidol | 939 | 1 | 0.49 (0.07, 3.51) | 0.49 (0.13) | −0.60 (−5.30, 4.11) | |
| Bromperidol | 113 | 1 | 4.14 (0.58, 29.68) | 4.11 (0.27) | 0.58 (−4.06, 5.43) | |
| Pipamperone | 15 | 0 | – | – | – | |
| Spiperone | 0 | 0 | – | – | – | |
| Timiperone | 9 | 0 | – | – | – | |
| Propericiazine | 85 | 0 | – | – | – | |
| Prochlorperazine | 143 | 0 | – | – | – | |
| Perphenazine | 17 | 0 | – | – | – | |
| Fluphenazine | 89 | 0 | – | – | – | |
| Levomepromazine | 730 | 0 | – | – | – | |
| Chlorpromazine | 431 | 0 | – | – | – | |
| Sulpiride | 1395 | 12 | 4.05 (2.29, 7.16)* | 4.02 (24.15)* | 1.70 (−0.16, 3.56) | |
| Sultopride | 52 | 0 | – | – | – | |
| Nemonapride | 9 | 0 | – | – | – | |
| Pimozide | 39 | 0 | – | – | – | |
| Atypical antipsychotic | ||||||
| Perospirone | 416 | 0 | – | – | – | |
| Risperidone | 2629 | 11 | 1.95 (1.08, 3.54)* | 1.95 (4.17) | 0.84 (−1.08, 2.78) | |
| Paliperidone | 774 | 2 | 2.37 (0.59, 9.53) | 2.37 (0.51) | 0.70 (−3.16, 4.55) | |
| Blonanserin | 550 | 4 | 3.4 (1.27, 9.11)* | 3.39 (4.54)* | 1.19 (−1.80, 4.19) | |
| Olanzapine | 1825 | 2 | 0.51 (0.07, 3.51) | 0.5 (0.52) | −0.72 (−4.56, 3.13) | |
| Quetiapine | 1836 | 0 | – | – | ||
| Clozapine | 1283 | 11 | 4.03 (2.22, 7.31)* | 4.01 (21.77)* | 1.67 (−0.26, 3.61) | |
| Asenapine | 134 | 0 | – | – | – | |
| Aripiprazole | 2316 | 6 | 1.36 (0.61, 3.03) | 1.36 (0.26) | 0.37 (−2.15, 2.89) | |
| Brexpiprazole | 112 | 0 | – | – | – | |
| Zotepine | 279 | 5 | 8.48 (3.50, 20.58)* | 8.35 (25.39)* | 1.94 (−0.84, 4.65) | |
| Mosapramine | 4 | 0 | – | – | – | |
| Oxypertine | 6 | 0 | – | – | – | |
| Clocapramine | 0 | 0 | – | – | – | |
ROR: the reporting odds ratio, PRR: the proportional reporting ratio, IC: the information component, CI: the confidence interval
a) total number of reports from April 2004 to April 2019 in JADER
An asterisk(*) indicates that the adverse events are detected as signals
Table 3.
Signal scores for antipsychotics-associated “Hyperprolactinemia”
| total a) | Hyperprolactinemia | |||||
|---|---|---|---|---|---|---|
| n | ROR (95%CI) | PRR (X2) | IC (95%CI) | |||
| Typical antipsychotic | ||||||
| Haloperidol | 939 | 3 | 81.79 (25.76, 259.68)* | 80.89 (158.65)* | 1.95 (−1.47, 5.36) | |
| Bromperidol | 113 | 0 | – | – | – | |
| Pipamperone | 15 | 0 | – | – | – | |
| Spiperone | 0 | 0 | – | – | – | |
| Timiperone | 9 | 0 | – | – | – | |
| Propericiazine | 85 | 0 | – | – | – | |
| Prochlorperazine | 143 | 0 | – | – | – | |
| Perphenazine | 17 | 0 | – | – | – | |
| Fluphenazine | 89 | 4 | 149.56 (54.48, 410.63)* | 146.59 (424.31)* | 2.28 (−0.80, 5.36) | |
| Levomepromazine | 730 | 0 | – | – | – | |
| Chlorpromazine | 431 | 0 | – | – | – | |
| Sulpiride | 1395 | 13 | 283.29 (156.78, 511.89)* | 273.74 (2840.96)* | 3.73 (1.81, 5.65)* | |
| Sultopride | 52 | 0 | – | – | – | |
| Nemonapride | 9 | 0 | – | – | – | |
| Pimozide | 39 | 0 | – | – | – | |
| Atypical antipsychotic | ||||||
| Perospirone | 416 | 0 | – | |||
| Risperidone | 2629 | 13 | 190.01 (105.46–342.34)* | 185.67 (1919.94)* | 3.69 (1.78, 5.61)* | |
| Paliperidone | 774 | 23 | 1187.33 (728.48,1935.18)* | 1050.90 (17,778.71)* | 4.54 (2.96, 6.12)* | |
| Blonanserin | 550 | 5 | 184.22 (74.16, 457.61)* | 179.78 (683.21)* | 2.54 (−0.29, 5.37) | |
| Olanzapine | 1825 | 4 | 60.79 (22.27, 165.95)* | 60.30 (170.62)* | 2.22 (−0.83, 5.28) | |
| Quetiapine | 1836 | 1 | 15.24 (2.12,109.53)* | 15.21 (2.84) | 0.91 (−3.85, 5.66) | |
| Clozapine | 1283 | 0 | – | – | – | |
| Asenapine | 134 | 2 | 188.96 (45.76, 780.12)* | 184.14 (200.09) | 1.57 (−2.39, 5.53) | |
| Aripiprazole | 2316 | 0 | – | – | – | |
| Brexpiprazole | 112 | 0 | – | – | – | |
| Zotepine | 279 | 0 | – | – | – | |
| Mosapramine | 4 | 0 | – | – | – | |
| Oxypertine | 6 | 0 | – | – | – | |
| Clocapramine | 0 | 0 | – | – | – | |
ROR: the reporting odds ratio, PRR: the proportional reporting ratio, IC: the information component, CI: the confidence interval
a) total number of reports from April 2004 to April 2019 in JADER
An asterisk(*) indicates that the adverse events are detected as signals
Analysis of hyperprolactinemia using ROR detected signals with nine drugs: haloperidol, fluphenazine, sulpiride, risperidone, paliperidone, blonanserin, olanzapine, quetiapine and asenapine. In the analysis using PRR, signals were detected with seven drugs: haloperidol, fluphenazine, sulpiride, risperidone, paliperidone, blonanserin, and olanzapine. Signals were detected with three drugs, namely, sulpiride, risperidone, and paliperidone, by IC analysis. Analysis of benign and malignant breast neoplasms was done using ROR detected signals with five drugs: sulpiride, risperidone, blonanserin, clozapine, and zotepine. In the analysis using PRR, signals were detected with four drugs: sulpiride, blonanserin, clozapine, and zotepine. None of the drugs had signals detected using IC.
Effect of antipsychotic drugs on proliferation of MCF-7 cells
We used six antipsychotics for cell experiments, both of which were reported as “hyperprolactinemia” and “benign and malignant breast neoplasms” in the JADER. When the antipsychotics haloperidol, paliperidone, risperidone, sulpiride, olanzapine and blonanserin were added to MCF-7 cells at 2 and 32 μM, none of the drugs showed any effect of promoting the growth of MCF-7 cells. Conversely, MCF-7 cells exposed to 32 μM blonanserin had markedly suppressed proliferation (Fig. 1). Furthermore, when the effect of 2–32 μM blonanserin on the proliferation of MCF-7 cells was evaluated, proliferation was significantly suppressed at 24 μM or higher (Fig. 2).
Fig. 1.
Effect of Antipsychotic on the proliferation of MCF-7 cells as assessed by WST-8 assay. TAM, which is known to suppress the growth of MCF-7 cells, was also exposed. Values are the mean ± S.E.(n = 4). **p < 0.01 compared with control. HAL: Haloperidol, PAL: Paliperidone, RIS: Risperidone, SUL: Sulpiride, OLZ: Olanzapine, BNS: Blonanserin
Fig. 2.
Effect of Blonanserin on the proliferation of MCF-7 cells as assessed by WST-8 assay. Values are the mean ± S.E.(n = 4). **p < 0.01 compared with control. BNS: Blonanserin
Discussion
In the JADER analysis of antipsychotics related to the AEs of breast tumor, a signal was detected with five drugs using ROR and four drugs using PRR, and no signal was detected using IC. There are several methods for detecting signals in the AE spontaneous reporting database, and ROR, PRR, and IC were used in this study. It is known that the commonly used ROR and PRR are similar when the incidence of AEs is low. In addition, it has been noted that there are many false positives because of the inflation of the values due to random fluctuations [15]. On the other hand, the Bayesian method, IC, is designed to avoid inflation even in the event of few reports. Since there were few reports of AEs related to hyperprolactinemia and breast tumors due to the antipsychotics analyzed in this study, we focused on the results using IC. Our analysis study was based on the number of drugs and not on the number of cases. Therefore, it includes both single agents and combinations of agents.
Sulpiride, risperidone, and paliperidone, which had signals for hyperprolactinemia detected by IC analysis, were not detected in benign and malignant breast neoplasms. Although hyperprolactinemia due to antipsychotics is already known [1], a meta-analysis reported that patients with hyperprolactinemia did not have an increased risk of breast cancer [16]. The analyzed results of this study supported this paper. We also calculated chlorpromazine equivalents for the three drugs of sulpiride, risperidone, and Paliperidone. However, discussions were challenging because of the large number of missing values.
Typical, rather than atypical, antipsychotics are generally thought to cause hyperprolactinemia. Additionally, it has been reported that the higher the pituitary D2 receptor occupancy is, that is, the more difficult it is to cross the BBB, the higher the risk of hyperprolactinemia will be [17]. However, in the JADER used in this study, the total number of reports for atypical antipsychotics exceeds that for typical antipsychotics. In addition, there are large variations in the total number of reports due to differences in the amount of each antipsychotic drug used. Spontaneous reporting data, including JADER, contains subjective assessments, hence, duplicate reporting, underreporting, and reporting bias can affect analysis results. In addition, the date lacked detailed individual information. These are the limitations of the research. In addition to antipsychotics, H2 blockers, tricyclic antidepressants, SSRIs, antihypertensives, estrogen therapy, and opioids [18–22] among others, are known factors in drug-induced hyperprolactinemia. Therefore, concomitant medications may also have an impact in individual cases. In this study, there were cases in which fluphenazine and duloxetine were used in combination, and cases in which risperidone and sulpiride were used in combination with domperidone. However, it is difficult to comment of its impact on the results because details, such as the timing of combined use, are unknown, and the possibility of duplicate reporting cannot be ruled out.
We also confirmed whether the subjects had any disease that affects hyperprolactinemia.
Of the 68 cases of hyperprolactinemia who used antipsychotics, one had a pituitary tumor and the other had hypothyroidism. There were no other reports, such as polycystic ovary syndrome, that were shown to be associated with hyperprolactinemia.
In experiments with breast cancer cells, we confirmed the direct effects of antipsychotic drugs on cell proliferation. Since 2/3 of breast cancers are positive for estrogen receptors [23], we used ER(+) MCF-7 cells in our experiments. It has been reported that MCF-7 cells also express dopamine, serotonin acetylcholine receptors and sigma receptors [24–27]. Haloperidol, paliperidone, risperidone, sulpiride, and olanzapine showed no effects in the evaluation of cell proliferation 72 h after MCF-7 cell exposure to antipsychotics. Haloperidol has been reported to suppress MCF-7 cell proliferation which suggests that its action is sigma receptor mediated [9, 10]., but its effect could not be confirmed in our study. This may be due to differences in protocols such as culture conditions. Sulpiride, which has a D2 receptor blockade, does not act on MCF-7 cells by itself, but it has been shown to increase responsiveness to dexamethasone [28]. Our experiments also showed that sulpiride had no effect on the proliferation of MCF-7 cells. Phenothiazines have also been shown to inhibit the PDK1/Akt pathway, which plays an important role in cell survival, proliferation, and tumorigenesis [29]. On the other hand, bromocriptine, which has a dopamine receptor agonistic effect, has also been shown to induce apoptosis via the D2 receptor and inhibit MCF-7 proliferation [30]. An antipsychotic drug that induces hyperprolactinemia has been shown to promote the progression of precancerous cells to cancerous cells via JAK/STAT5 [31]. Increased expression levels of DRD2 mRNA have been reported in breast cancer patients [32], so it is expected that the risk of breast cancer with antipsychotics and the actions and mechanisms mediated by dopamine receptors will be further elucidated.
Blonanserin was an antipsychotic drug launched in Japan in 2008 and is used in only some Asian countries. The blonanserin patch was launched in 2019, and it is expected that the number of patients using it will increase. Blonanserin, unlike most atypical antipsychotics, has a higher affinity for dopamine D2 than the serotonin 5-HT2A receptor [33]. In cultured cells and in animal studies, D2 receptor antagonists have antitumor effects [29, 34], and blonanserin, which has a higher affinity for D2 receptors than other atypical antipsychotics, may have a significant inhibitory effect on MCF-7 cell proliferation. The incidence of hyperprolactinemia has been reported to be low in patients who continue to receive blonanserin [35]. In our analysis, there was no IC signal for blonanserin in hyperprolactinemia. The effect of blonanserin on breast cancer cells was confirmed in SUM159, a triple-negative breast cancer cell line used often in brain metastasis studies, with an IC50 of > 100 μM [36]. Our results are the first report to clarify the effect of blonanserin on the proliferation of MCF-7 cells. In this study, a significant growth inhibitory effect was observed at 24 μM, so the effect may differ depending on the cell type. The clinical significance of this effect is not yet clear. The maximum blood concentration of blonanserin in humans is approximately 2 nM, which is in the nM rather than μM range. In addition, the effects of other antipsychotics on MCF-7 were confirmed at concentrations equal to or higher than blood levels. Other antipsychotics also showed antiproliferative effects on MCF-7 cells at similar concentrations, and there may also be class effects.
Although not shown in this paper, we predicted the binding ability of each antipsychotic drug to the estrogen receptor using the ADMET Predictor™ software, which can predict the binding ability to the estrogen receptor from a structure-activity relationship. Among the six antipsychotics used in this study, blonanserin and its major metabolites showed the highest predicted value to bind to the estrogen receptor. If the inhibitory effect of blonanserin on the growth of MCF-7 cells is mediated by the estrogen receptor, there is a possibility that such a difference in binding ability may have an influence. In addition, although our software cannot predict the ability of blonanserin to bind to the prolactin receptor, it has been reported that diphenylbutylpiperidine antipsychotics bind to the prolactin receptor and suppress signal transduction [37]. Therefore, other antipsychotics may act via the prolactin receptor.
This is the first report to evaluate the association between antipsychotics and the development of breast cancer using the JADER. Furthermore, we confirmed the effects of antipsychotic drugs, which were reported in the JADER for hyperprolactinemia and breast cancer, on the proliferation of MCF-7 cells. Since typical antipsychotics and atypical antipsychotics simply cannot be compared, it is necessary to select the appropriate drug for each patient [38]. Various factors are related to the influence of antipsychotic drugs in terms of the occurrence and progression of breast cancer, and this may be a consideration in choosing the remedy that is least likely to cause hyperprolactinemia and that has a suppressive effect on the growth of breast cancer cells from the viewpoint of side effects.
Conclusions
Analysis of the JADER using IC did not reveal signals for the development of breast tumors due to antipsychotic drugs. In the in vitro experiments, MCF-7 cell growth was not promoted by haloperidol, paliperidone, risperidone, sulpiride, olanzapine, or blonanserin; however, blonanserin was observed to suppress MCF-7 cell growth.
Acknowledgments
The authors would like to thank Enago (www.enago.jp) for the English language review.
Abbreviations
- JADER
Japanese Adverse Drug Event Report database
- PMDA
Pharmaceuticals and Medical Devices Agency
- AE
adverse event
- MCF-7
Michigan Cancer Foundation-7
- ROR
reporting odds ratio
- PRR
proportional reporting ratio
- IC
information component
- ER
estrogen receptor
- CI
confidence interval
- DMSO
dimethyl sulfoxide
- FBS
fetal bovine serum
- RPMI
Roswell Park Memorial Institute media
- TAM
tamoxifen
- PBS
phosphate-buffered saline
- SSRI
selective serotonin reuptake inhibitor
- PDK
phosphoinositide-dependent kinase
- DRD
dopamine receptor gene
- WHO
World Health Organization
- ATC
Anatomical Therapeutic Chemical
Authors’ contributions
FI designed the study. TM performed all the analyses and experiments and drafted the manuscript. RI and SY helped with the cell experiments. FI and MW reviewed the manuscript. All authors read and approved the final manuscript.
Funding
This work was supported by JSPS KAKENHI Grant Number 20 K16455.
Availability of data and materials
The dataset acquired and analyzed in this study will be made available to the responsible authors upon due request.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291–2314. doi: 10.2165/00003495-200464200-00003. [DOI] [PubMed] [Google Scholar]
- 2.Mazziotti G, Mancini T, Mormando M, De Menis E, Bianchi A, Doga M, et al. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. 2011;14:299–306. doi: 10.1007/s11102-011-0293-4. [DOI] [PubMed] [Google Scholar]
- 3.Gulbinat W, Dupont A, Jablensky A, Jensen OM, Marsella A, Nakane Y, et al. Cancer incidence of schizophrenic patients. Results of record linkage studies in three countries. Br J Psychiatry Suppl. 1992:75–83. [PubMed]
- 4.Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5:1749–1768. doi: 10.1001/jamaoncol.2019.2996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, et al. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 2013;73:4810–4819. doi: 10.1158/0008-5472.CAN-13-0665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Pottegard A, Lash TL, Cronin-Fenton D, Ahern TP, Damkier P. Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study. Br J Clin Pharmacol. 2018;84:2152–2161. doi: 10.1111/bcp.13661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Azoulay L, Yin H, Renoux C, Suissa S. The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res Treat. 2011;129:541–548. doi: 10.1007/s10549-011-1506-2. [DOI] [PubMed] [Google Scholar]
- 8.George A, Sturgeon SR, Hankinson SE, Shadyab AH, Wallace RB, Reeves KW. Psychotropic medication use and postmenopausal breast Cancer risk. Cancer Epidemiol Biomark Prev. 2020;29:254–256. doi: 10.1158/1055-9965.EPI-19-0776. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Strobl JS, Melkoumian Z, Peterson VA, Hylton H. The cell death response to gamma-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide. Breast Cancer Res Treat. 1998;51:83–95. doi: 10.1023/A:1006046604062. [DOI] [PubMed] [Google Scholar]
- 10.Brent PJ, Pang GT. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol. 1995;278:151–160. doi: 10.1016/0014-2999(95)00115-2. [DOI] [PubMed] [Google Scholar]
- 11.Badran A, Tul-Wahab A, Zafar H, Mohammad N, Imad R, Ashfaq Khan M, et al. Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. PLoS One. 2020;15:e0235676. doi: 10.1371/journal.pone.0235676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519–523. doi: 10.1002/pds.1001. [DOI] [PubMed] [Google Scholar]
- 13.Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483–486. doi: 10.1002/pds.677. [DOI] [PubMed] [Google Scholar]
- 14.Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315–321. doi: 10.1007/s002280050466. [DOI] [PubMed] [Google Scholar]
- 15.Fujita T. Signal detection of adverse drug reactions. Jpn J Pharmacoepidemiol. 2009;14(1):27–36. doi: 10.3820/jjpe.14.27. [DOI] [Google Scholar]
- 16.Dekkers OM, Ehrenstein V, Bengtsen M, Farkas DK, Pereira AM, Sørensen HT, et al. Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. Eur J Endocrinol. 2015;173:269–273. doi: 10.1530/EJE-15-0282. [DOI] [PubMed] [Google Scholar]
- 17.Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, et al. Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010;71:1131–1137. doi: 10.4088/JCP.08m04307yel. [DOI] [PubMed] [Google Scholar]
- 18.Agrawal P, Pursnani N, Parihar A, Singh B. Ranitidine-induced galactorrhea in a postmenopausal female. J Family Med Prim Care. 2019;8:3057–3058. doi: 10.4103/jfmpc.jfmpc_633_19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mahasuar R, Majhi P, Ravan JR. Euprolactinemic galactorrhea associated with use of imipramine and escitalopram in a postmenopausal woman. Gen Hosp Psychiatry. 2010;32:341.e11–3. [DOI] [PubMed]
- 20.Park YM. Serum prolactin levels in patients with major depressive disorder receiving selective serotonin-reuptake inhibitor Monotherapy for 3 months: a prospective study. Psychiatry Investig. 2017;14:368–371. doi: 10.4306/pi.2017.14.3.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Krysiak R, Okopieh B, Herman ZS. Verapamil-induced hyperprolactinemia--a case report. Pol Arch Med Wewn. 2005;113:155–158. [PubMed] [Google Scholar]
- 22.de Vries F, Bruin M, Lobatto DJ, Dekkers OM, Schoones JW, van Furth WR, et al. Opioids and their endocrine effects: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105:1020–1029. doi: 10.1210/clinem/dgz022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995;87:446–451. doi: 10.1093/jnci/87.6.446. [DOI] [PubMed] [Google Scholar]
- 24.Borcherding DC, Tong W, Hugo ER, Barnard DF, Fox S, LaSance K, et al. Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer. Oncogene. 2016;35:3103–3113. doi: 10.1038/onc.2015.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Hejazi SH, Ahangari G, Deezagi A. Alternative viewpoint against breast Cancer based on selective serotonin receptors 5HTR3A and 5HTR2A antagonists that can mediate apoptosis in MCF-7 cell line. Curr Drug Discov Technol. 2015;12:240–249. doi: 10.2174/1570163813666151126215210. [DOI] [PubMed] [Google Scholar]
- 26.Salem AR, Martínez Pulido P, Sanchez F, Sanchez Y, Español AJ, Sales ME. Effect of low dose metronomic therapy on MCF-7 tumor cells growth and angiogenesis. Role of muscarinic acetylcholine receptors. Int Immunopharmacol. 2020;84:106514. doi: 10.1016/j.intimp.2020.106514. [DOI] [PubMed] [Google Scholar]
- 27.Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55:408–413. [PubMed] [Google Scholar]
- 28.Li J, Yao QY, Xue JS, Wang LJ, Yuan Y, Tian XY, et al. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer. Acta Pharmacol Sin. 2017;38:1282–1296. doi: 10.1038/aps.2017.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Choi JH, Yang YR, Lee SK, Kim SH, Kim YH, Cha JY, et al. Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival. Ann N Y Acad Sci. 2008;1138:393–403. doi: 10.1196/annals.1414.041. [DOI] [PubMed] [Google Scholar]
- 30.Pornour M, Ahangari G, Hejazi SH, Deezagi A. New perspective therapy of breast cancer based on selective dopamine receptor D2 agonist and antagonist effects on MCF-7 cell line. Recent Pat Anticancer Drug Discov. 2015;10:214–223. doi: 10.2174/1574892810666150416111831. [DOI] [PubMed] [Google Scholar]
- 31.Johnston AN, Bu W, Hein S, Garcia S, Camacho L, Xue L, et al. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018;20:42. doi: 10.1186/s13058-018-0969-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Majid Pornour GA, Seyed Hesam Hejazi, H RA, and Mohamad Esmail Akbari. Dopamine Receptor Gene (DRD1-DRD5) Expression Changes as Stress Factors Associated with Breast Cancer. Asian Pac J Cancer Prev. 2014;15:10339–43. [DOI] [PubMed]
- 33.T. Une SK Pharmacological profile of blonanserin. Jpn J Clin Psychopharmacol. 2007;10:1263–1272. [Google Scholar]
- 34.Karpel-Massler G, Kast RE, Westhoff MA, Dwucet A, Welscher N, Nonnenmacher L, et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. J Neuro-Oncol. 2015;122:21–33. doi: 10.1007/s11060-014-1688-7. [DOI] [PubMed] [Google Scholar]
- 35.Takahashi S, Suzuki M, Uchiyama M. One-year follow-up of serum prolactin level in schizophrenia patients treated with Blonanserin: a case series. Psychiatry Investig. 2015;12:566–568. doi: 10.4306/pi.2015.12.4.566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, et al. Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep. 2018;8:15753. doi: 10.1038/s41598-018-33740-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Dandawate P, Kaushik G, Ghosh C, Standing D, Ali Sayed AA, Choudhury S, et al. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology. 2020;158:1433–49.e27. [DOI] [PMC free article] [PubMed]
- 38.Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41. doi: 10.1016/S0140-6736(08)61764-X. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The dataset acquired and analyzed in this study will be made available to the responsible authors upon due request.